Withdrawal of the marketing authorisation application: ivosidenib (Tibsovo)

The company withdrew its application for treatment of acute myeloid leukaemia because the CHMP considered that the available data were not sufficient to conclude on a positive benefit-risk balance.

Source:

European Medicines Agency